Voyager spells out its $92M IPO pitch as Wall Street sours on biotech

Damian Garde Gene therapy developer Voyager Therapeutics is angling for as much as $ 92 million in a planned IPO, braving choppy waters for biotech after a string of disappointing ...

Biotech notches another $2B VC quarter, but can it last?

Damian Garde Biotech venture capital investments remain on pace for a record year after racking up another $ 2 billion in the third quarter, but some current shakiness in the public ...

The Shkreli scandal leaves a big mess for biotech to clean up

John Carroll The industry now has to deal with the fact that drug pricing has taken center stage in presidential politics. And the story of Daraprim, Martin Shkreli and price gouging ...

Volatile valuations make biotech a haven for short sellers

Damian Garde The years-long glut of biotech IPOs has flooded the public markets with high-risk life sciences companies, and shorts have taken a particular interest in those newly public ...

Genzyme vets raise $37.5M for a new cancer biotech

Damian Garde The stealthy X4 Pharmaceuticals, run by some of former Genzyme execs, has raised $ 37.5 million to fund its work on new cancer treatments. FierceBiotech News

A biotech startup grows out of GlaxoSmithKline’s discarded NC R&D

Damian Garde GlaxoSmithKline is laying off nearly 1,000 employees in North Carolina in an effort to trim its R&D costs, cutting deep into the biotech ecosystem in Research Triangle ...

Lilly’s CEO keeps faith in the pipeline as biotech gets ‘too expensive’

Damian Garde Eli Lilly is staking its future on a pair of high-stakes Phase III programs, shying away from any big biotech buyouts as sticker prices continue to soar. FierceBiotech ...

Playing catch-up on Big Biotech goal, Shire broadens M&A focus

Carly Helfand Shire's $ 54 billion tie-up with AbbVie–and the subsequent cancellation of that deal–shook up employees and stalled CEO Flemming Ornskov's plans to ...

UPDATED: Celgene chief Bob Hugin isn’t done betting on ‘binary’ biotech deals

John Carroll By all accounts, the bidding war for Receptos was intense. But for Celgene CEO Bob Hugin and his go-to deals chief George Golumbeski, strategically this was exactly the ...

Biotech legend Lee Hood gambles $36M on a plan to revolutionize healthcare

John Carroll FierceBiotech News

UPDATED: Biogen R&D chief Doug Williams joins exodus to run a biotech upstart

John Carroll Biogen's high-profile R&D chief, Doug Williams, has heard the siren song of a biotech startup. Near midday on Friday, the Big Biotech put out word that Williams ...

Viehbacher returns to lead Swiss billionaire’s $2B biotech fund

Alok Saboo FierceBiotech News
Page 2 of 1812345...10...Last »
© 2018 Global Regulatory Science. All rights reserved. Site Admin · Entries RSS · Comments RSS